Management Team
Peter S. Lawrence
President and Chief Operating Officer
Mr. Lawrence joined ArQule in April 2006 from Pod Holding Ltd., an international venture capital firm which he co-founded in 2001 and where he most recently served as general partner. He helped drive the strategic growth of that firm, including deal sourcing and structuring, syndication and business expansion activities. Mr. Lawrence served as lead partner on investment activities for a number of companies, including the cancer company, Pintex Pharmaceuticals. Previously, Mr. Lawrence was an attorney and partner at Mintz, Levin, Cohn, Ferris Glovsky and Popeo, P.C., from 1991 to 2001. At Mintz Levin, he served as external corporate counsel to public and private companies, managed a transactional legal practice and provided strategic guidance to clients through periods of rapid growth and transformative corporate events. His public financing experiences include the initial public offering and numerous financings for America Online Inc. (AOL), as well as public financings for Biogen, Human Genome Sciences, Hybridon and many other companies. He worked on numerous mergers and acquisitions, including Roche/Compuchem, AOL/Time Warner, Steinway Piano, DEC/Intel, and Mitotix/GPC Biotech. Mr. Lawrence worked at Gaston & Snow from 1989 to 1991 in the firm’s Corporate Law Department. He holds a Bachelor’s degree from Amherst College and a J.D. from Boston University School of Law.
Thomas C. K. Chan, Ph.D.
Senior Vice President, Discovery and Preclinical Development
Dr. Chan joined ArQule in December, 2005 as vice president, pharmacology and toxicology. He was promoted to his current position in January, 2007 and manages all research activities and new oncology drug candidate selection at ArQule. He is also responsible for toxicology and clinical pharmacology of the Company's drug candidates currently in human clinical trials. Dr. Chan was previously at MacroChem Corporation from 2001 to 2005, where he served as chief technology officer and vice president, research and development. He was also senior director, pharmacology and toxicology, at EPIX Medical, Inc. from 1997 to 2000, and director of therapeutic development at Creative Biomolecules from 1993 to 1997. Prior to his career in industry, Dr. Chan held a number of academic appointments, most recently as associate director of the Purdue University Cancer Center and a tenured professor at Purdue University and Indiana University. He is a member of several NIH Study Sections and consults for the U.S. Department of Defense on their prostate and breast cancer research programs. Dr. Chan received his doctorate in pharmacology/toxicology from the University of British Columbia and was a postdoctoral fellow in hematology/oncology at the Cancer Center of the University of California, San Diego School of Medicine.
Anthony S. Messina
Vice President of Human Development
Mr. Messina joined the Company in 1997 and has served as the Vice President of Human Development since June 1999. Prior to joining ArQule, Mr. Messina was Vice President for Camden Consulting (1994-1997) and Human Resources Manager for Varian Associates (1978-1994). He received his B.B.A. in management from the University of Massachusetts and has an M.Ed in human resources from Boston University.
Nigel J. Rulewski, M.B., B.S., D.R.C.O.G., D.C.H.
Chief Medical Officer
Dr. Rulewski joined ArQule in August 2006 from BioAccelerate Holding Inc., a pharmaceutical development organization, where he was senior vice president. He brings to ArQule more than two decades of experience in clinical research, product development, regulatory affairs, commercialization, corporate planning and licensing activities. At BioAccelerate, Dr. Rulewski was responsible for all aspects of licensing and product development in the oncology area. Previously, as vice president, medical affairs and chief medical officer at Astra USA, Dr. Rulewski negotiated the approval of eight New Drug Applications (NDAs) and had responsibility for all issues pertaining to drug development in the U.S., including interactions with the U.S. Food and Drug Administration (FDA). He previously served as medical director at Serono Laboratories, where he managed three research groups, medical information and drug safety. He was also associate medical director and medical director, international operations, at Fisons Corporation. Dr. Rulewski practiced medicine in the United Kingdom following his graduation from St. Bartholomew's Hospital Medical School, University of London.